He also reviews the development of menin inhibitors in AML, including recent regulatory advances in the relapsed/refractory ...
Earnings call Arvinas delivered a milestone quarter with FDA approval and out-licensing of VEPPANU (vepdegestrant), marking the first-ever PROTAC degrader approval. Q1 2026 revenue fell sharply to $15 ...
Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s Faslodex but showed no such significant benefit in the intention-to-treat analysis ...
SAN FRANCISCO , CA, UNITED STATES, March 30, 2026 /EINPresswire.com/ — Ainnocence, a next-generation AI drug discovery company, announces the commercial ...
Platform screens up to 10 billion compounds in hours, delivering wet-lab-ready candidates in weeks without requiring 3D protein structures SAN FRANCISCO , CA, UNITED ...
In a significant advancement, cancer researchers have found a long-sought way to overcome a critical design barrier in the generation of small-molecule chemical tools and drugs that work by targeted ...
PROTACs (Proteolysis Targeting Chimeras) offer a revolutionary strategy to degrade proteins previously considered "undruggable." While the importance of the target protein ligand and linker is ...
Currently, most drugs have their mode of action based on occupation-oriented pharmacology (proteins modulation through temporary inhibition by association and dissociation). Alternative modes of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results